BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kreisel W, Deibert P, Kupcinskas L, Sumskiene J, Appenrodt B, Roth S, Neagu M, Rössle M, Zipprich A, Caca K, Ferlitsch A, Dilger K, Mohrbacher R, Greinwald R, Sauerbruch T. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis 2015;47:144-50. [PMID: 25483910 DOI: 10.1016/j.dld.2014.10.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Kang SH, Kim MY, Baik SK. Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon. Hepatol Int 2018;12:112-21. [DOI: 10.1007/s12072-017-9806-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
2 Kim HL, Kim YJ, Kim KH, Lee SP, Kim HK, Sohn DW, Oh BH, Park YB. Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy. Hypertens Res 2015;38:597-604. [PMID: 25832922 DOI: 10.1038/hr.2015.46] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
3 Schwabl P, Laleman W. Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf). 2017;5:90-103. [PMID: 28533907 DOI: 10.1093/gastro/gox011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
4 Uschner FE, Glückert K, Paternostro R, Gnad T, Schierwagen R, Mandorfer M, Magdaleno F, Ortiz C, Schwarzkopf K, Kamath PS, Alessandria C, Boesecke C, Pfeifer A, Reiberger T, Kreisel W, Sauerbruch T, Ferlitsch A, Trebicka J, Klein S. Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. Liver Int 2020;40:2228-41. [PMID: 32627946 DOI: 10.1111/liv.14586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Schwarzer R, Seeland B, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. Liver Int 2018;38:1427-36. [PMID: 29368385 DOI: 10.1111/liv.13704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
6 Kreisel W, Lazaro A, Trebicka J, Grosse Perdekamp M, Schmitt-Graeff A, Deibert P. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. Int J Mol Sci 2021;22:10372. [PMID: 34638713 DOI: 10.3390/ijms221910372] [Reference Citation Analysis]
7 Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A, Kreisel W. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World J Gastroenterol 2018; 24(38): 4356-4368 [PMID: 30344420 DOI: 10.3748/wjg.v24.i38.4356] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
8 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
9 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kimer N, Wiese S, Mo S, Møller S, Bendtsen F. Advances in the treatment of portal hypertension in cirrhosis. Expert Rev Gastroenterol Hepatol 2016;10:961-9. [PMID: 26982499 DOI: 10.1586/17474124.2016.1166952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Palaniyappan N, Fallowfield JA. Editorial: metformin for portal hypertension-old dog, new tricks? Aliment Pharmacol Ther 2021;54:345-6. [PMID: 34236093 DOI: 10.1111/apt.16484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li H. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Dig Liver Dis 2021:S1590-8658(21)00375-3. [PMID: 34344577 DOI: 10.1016/j.dld.2021.07.006] [Reference Citation Analysis]
13 Jagdish RK, Kamaal A, Shasthry SM, Benjamin J, Maiwall R, Jindal A, Choudhary A, Rajan V, Arora V, Bhardwaj A, Kumar G, Kumar M, Sarin SK. Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial. Hepatol Int 2021. [PMID: 34775577 DOI: 10.1007/s12072-021-10264-w] [Reference Citation Analysis]
14 Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. Expert Opin Emerg Drugs 2016;21:167-81. [PMID: 27148904 DOI: 10.1080/14728214.2016.1184647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
15 Brusilovskaya K, Königshofer P, Lampach D, Szodl A, Supper P, Bauer D, Beer A, Stift J, Timelthaler G, Oberhuber G, Podesser BK, Seif M, Zinober K, Rohr-Udilova N, Trauner M, Reiberger T, Schwabl P. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. United European Gastroenterol J 2020;8:1174-85. [PMID: 32878579 DOI: 10.1177/2050640620944140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
16 Kim HY, Kim KH. Udenafil as a Therapeutic Option for Pulmonary Arterial Hypertension. Korean Circ J 2019;49:361-2. [PMID: 30808087 DOI: 10.4070/kcj.2019.0023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A, Deibert P. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int J Mol Sci 2020;21:E6223. [PMID: 32872119 DOI: 10.3390/ijms21176223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Lee JH, Lee DY, Kang KK, Jeong EJ, Staatz CE, Baek IH. Gender differences and dose proportionality in the toxicokinetics of udenafil and its active metabolite following oral administration in rodents. Toxicol Appl Pharmacol 2021;410:115339. [PMID: 33221319 DOI: 10.1016/j.taap.2020.115339] [Reference Citation Analysis]
19 Hwang IC, Kim YJ, Park JB, Yoon YE, Lee SP, Kim HK, Cho GY, Sohn DW. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovasc Disord 2017;17:150. [PMID: 28606099 DOI: 10.1186/s12872-017-0576-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
20 Ala M, Mohammad Jafari R, Dehpour AR. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. Fundam Clin Pharmacol 2021;35:235-59. [PMID: 33226665 DOI: 10.1111/fcp.12633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martínez-Alcocer A, Gracia-Sancho J, Guixé-Muntet S, Fernández-Iglesias A. The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. Cancers (Basel) 2021;13:5719. [PMID: 34830874 DOI: 10.3390/cancers13225719] [Reference Citation Analysis]
22 Deibert P, Lazaro A, Stankovic Z, Schaffner D, Rössle M, Kreisel W. Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up. World J Gastroenterol 2018; 24(3): 438-444 [PMID: 29391766 DOI: 10.3748/wjg.v24.i3.438] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Chang SA, Kim HK, Chang HJ, Kim DK. Acute Hemodynamic Changes after Single Administration of Udenafil in Pulmonary Arterial Hypertension: a Phase IIa Study. Korean Circ J 2019;49:353-60. [PMID: 30808080 DOI: 10.4070/kcj.2018.0281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
24 Chang HJ, Song S, Chang SA, Kim HK, Jung HO, Choi JH, Lee JS, Kim KH, Jeong JO, Lee JH, Kim DK. Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial. Clin Ther 2019;41:1499-507. [PMID: 31202506 DOI: 10.1016/j.clinthera.2019.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Schwabl P, Brusilovskaya K, Supper P, Bauer D, Königshofer P, Riedl F, Hayden H, Fuchs CD, Stift J, Oberhuber G, Aschauer S, Bonderman D, Gnad T, Pfeifer A, Uschner FE, Trebicka J, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Trauner M, Reiberger T. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Sci Rep 2018;8:9372. [PMID: 29921982 DOI: 10.1038/s41598-018-27656-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
26 Bunchorntavakul C, Reddy KR. Pharmacologic Management of Portal Hypertension. Clin Liver Dis 2019;23:713-36. [PMID: 31563219 DOI: 10.1016/j.cld.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]